Full Press Release Details
Corporate Presentation January 2024
Legal Disclosure This presentation
contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of forward-looking words such as "may",
"anticipate", "believe", "could', "expect", "should", "plan", "intend", "estimate", "will", "potential" and "ongoing", among others, although not all forward-looking statements contain these identifying words. These forward-looking statements
include statements about the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and
completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; our ability to successfully manufacture our drug substances and product
candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our
development candidates and product candidates; our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; our ability to obtain and maintain regulatory approval of our
product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our financial performance; and the implementation of our business model, and strategic plans for our business and
product candidates. Except as otherwise noted, these forward-looking statements speak only as of the date of this presentation, and we undertake no obligation to update or revise any of such statements to reflect events or circumstances occurring
after this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking
statements as predictions of future events. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see
the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important
factors in our other subsequent filings with the Securities and Exchange Commission. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those
projected in the forward-looking statements. We caution you not to place undue reliance on the forward-looking statements contained in this presentation. This presentation discusses product candidates that are under preclinical or clinical
evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as
a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. This presentation shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or other jurisdiction.
Aura Biosciences - Developing a
Novel Class of Drugs in Oncology Ocular Oncology Franchise Choroidal Melanoma - Global Ph 3 CoMpass Trial: FPI was Q4 2023 Most US sites activated; Trial actively enrolling Special Protocol Assessment (SPA) Agreement with FDA Ph 3 assumptions
supported by Ph 2 data Choroidal Metastasis - Ph 2 trial planned to initiate in mid-2024 Second ocular indication potentially doubles market opportunity Urologic Oncology Franchise Clinical complete response in first patient with single dose
Data supports dual mechanism Updated protocol includes both NMIBC and MIBC Strong Cash Position Current cash runway expected to fund operations into 2H 2026
Pipeline Targeting Life-Threatening
Cancers with High Unmet Needs Program OTHER SOLID TUMORS OCULAR ONCOLOGY Preclinical Phase 1 Phase 2 Phase 3 Planned Milestones Choroidal Metastasis (Multiple primary cancers with metastasis in the eye e.g., Breast and Lung) Primary Choroidal
Melanoma (Suprachoroidal administration) Cancers of the Ocular Surface Bladder Cancer (NMIBC and MIBC) Other HSPG* Expressing Tumors (e.g., Cutaneous melanoma, HNSCC) YE 2024 - Ph 2 data Mid-2024 - Ph 1 data Global Commercial Rights for
All Product Candidate Indications *VDCs bind to a subset of modified tumor associated glycosaminoglycans (GAGs) that are part of the heparan sulphate chain of HSPGs. Schiller et al. Viruses 2022, 14(8), 1656 YE 2024 - Majority
of sites activated globally
Targeted Oncology Platform: Virus-Like
Drug Conjugates (VDCs) Virus-Like Particle Conjugated to a Cytotoxic Payload Selective Binding to Tumor Associated HSPGs* Virus-Like Particle (VLP) Virus-Like Drug Conjugate (VDC) Cx Cytotoxic Drug Kines et al; International Journal of Cancer,
138;901-911, February 2016; Kines et al; Molecular Cancer Therapeutics, 17(2) February 2018; Kines et al; Cancer Immunology Research, May 2021 Potential Key Differentiation: Potency, Multivalent Binding and Selectivity Potential Treatment of
Multiple Solid Tumors *VDCs bind to a subset of modified tumor associated glycosaminoglycans (GAGs) that are part of the heparan sulphate chain of HSPGs. Schiller et al. Viruses 2022, 14(8), 1656
Bel-sar is a VDC with a Novel Dual
Mechanism of Action Light Activatable Drug Bel-sar Bel-sar is a novel VDC that consists of VLP conjugated to ~200 molecules of light activatable drug Potential Key Differentiation: Agnostic to Genetic Mutations, Less Susceptible to Resistance
Mechanisms, Long Term Anti-tumor Immunity Kines et al; Cancer Immunology Research, May 2021 VDCs bind to a subset of modified tumor associated glycosaminoglycans (GAG) that are part of the heparan sulphate chain of HSPGs. Schiller et al.
Viruses 2022, 14(8), 1656 Bel-sar - Belzupacap Sarotalocan Reactive oxygen species disrupts cell membrane and organelles
Ocular Oncology Franchise Bel-sar INN:
belzupacap sarotalocan Target Indications: Early-Stage Choroidal Melanoma Choroidal Metastasis Other Ocular Cancers
Primary Choroidal Melanoma-High
Unmet Medical Need Choroidal Melanoma is a Rare and Life-Threatening Primary Ocular Cancer with No Drugs Approved 1. Heiting, G. Iris/uvea of the eye. Accessed Oct. 3, 2023. https://www.allaboutvision.com/en-gb/resources/uvea-iris-choroid/ 2. Kaliki
S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241-257. doi:10.1038/eye.2016.275 3. Clearview & Putnam & Assoc. Market Research Most common primary intraocular cancer in adults2 Impacts ~11,000
patients in US/Europe per year3 ~80% patients diagnosed with early-stage disease3 Choroid is 90% of the uvea1 50% of patients develop metastasis within 15 years (metastatic uveal melanoma)2 choroid Uvea: Choroid, Ciliary Body and Iris
Radiotherapy is the Standard of Care
for Early-Stage Disease Surgical treatment of large choroidal melanoma with ruthenium 106 plaque brachytherapy2 1. Up To Date. Plaque brachytherapy for uveal melanoma. Accessed September 20, 2023.
https://ykhoa.org/d/image.htm?imageKey=ONC/116591 2. Kim M, Lee SM, Lee. Surgical treatment of a large choroidal melanoma. American Academy of Optometry 2022 Video Program. March 1, 2023. Accessed September 20, 2023.
https://www.aao.org/education/annual-meeting-video/surgical-treatment-of-large-choroidal-melanoma 3. Peddada KV, Sangani R, Menon H, Verma V. Complications and adverse events of plaque brachytherapy for ocular melanoma. J Contemp Brachytherapy.
2019;11(4):392-397. doi:10.5114/jcb.2019.87407 (A) Schematic drawing showing a Collaborative Ocular Melanoma Study (COMS) style plaque sutured to the sclera overlying the location of the uveal melanoma1 (B) Intraoperative photograph showing COMS
plaque in place. The plaque stays in place for 3 to 7 days1 Plaque Brachytherapy for Choroidal Melanoma Requires Invasive Surgery with Irreversible Complications and Does Not Prevent Metastasis Maculopathy, Cataract, Glaucoma, Vitreous Detachment
and Vitreous Hemorrhage are Common Vision Threatening Complications of Brachytherapy3
Up to 87% of Patients Will be
Blinded when Treated with Radiotherapy Jarczak J, Karska-Basta I, Romanowska-Dixon B. Deterioration of visual acuity after brachytherapy and proton therapy of uveal melanoma, and methods of counteracting this complication based on recent
publications. Medicina (Kaunas). 2023;59(6):1131. Tsui I, Beardsley RM, McCannel TA, Oliver SC, et al. Visual acuity, contrast sensitivity and color vision three years after iodine-125 brachytherapy for choroidal and ciliary body melanoma. Open
Ophthalmol J. 2015;9:131-5. Normal Vision Vision with Reduced Contrast Sensitivity Visual Acuity, Color Vision and Contrast Sensitivity Decrease Significantly within the First Year after Treatment and Continue to Decrease Over Time Proportion of
Patients Legally Blind (BCVA 20/200) after Brachytherapy1,2 Contrast Sensitivity Diminishes Significantly within the First Year after Brachytherapy and Continues to Deteriorate Over Time2
Benefit/Risk of Radiotherapy Drives
"Watch and Wait" in Patients with Early-Stage Disease Brachytherapy: Vision Loss/Blindness Clearview & Putnam & Assoc. Market Research Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond).
2017;31(2):241-257. doi:10.1038/eye.2016.275 (~8,000)1 (~2,300)1 (~2,000)2 Indeterminate Lesions and Small PCM Medium/large PCM Prevalence: Patients US/EU Early Stage Late Stage Metastatic Disease Systemic Chemotherapy (KIMMTRAK) Current Treatment
Watch and Wait/Brachytherapy Most of the Addressable Population is Untreated Due to Risk of Treatment Related Vision Loss and Severe Comorbidities inevitably
Bel-sar has the Potential to be the
First Approved Therapy in Primary Choroidal Melanoma No radiation-related morbidity Preservation of vision Local tumor control Opportunity to treat early and reduce risk of metastases Improvement in safety and quality of life Bel-sar is Delivered by
Simple Suprachoroidal Injection Goals of Treatment suprachoroidal Light Activation with Standard Ophthalmic Laser Bel-sar - Belzupacap Sarotalocan 3-4h In-Office Two injections (2min. each) 30 min apart 10-30 min. procedure
Ocular Oncology Franchise
Represents a Multi-Billion Dollar Addressable Market Opportunity Ocular Oncology Franchise total addressable market (US/EU) ~80% of patients are diagnosed at the early stage (indeterminate lesions (ILs) and small tumors) Current radiotherapy
treatment Leaves ~87% of patients with major irreversible vision loss ~100 Ocular Oncologists in US/EU - focused call point <20 Field Based Team Intend to add small sales force to launch globally ~66,000 patients/year 1. ClearView
& Putnam & Assoc. Epidemiology Analysis Choroidal Melanoma and Choroidal Metastasis 2. American Cancer Society- Retinoblastoma statistics 3. Includes Conjunctival Melanoma, Primary Acquired Melanosis, Squamous Cell Carcinoma and Ocular
Multibillion $ addressable market opportunity Cancers of the Ocular Surface Retinoblastoma Choroidal Melanoma Choroidal Metastasis 11,000 patients/year1 20,000 patients/year1 500 patients/year2 ~35,000 patients/year3 11,000 patients/year Choroidal
Melanoma patients diagnosed each year (US/EU)
Bel-Sar has the Potential to be an
Effective, Vision Preserving Therapy for the Treatment of Indeterminate Lesions and Small Choroidal Melanoma Potential Future Patient Treatment Journey Treatment First Line Treatment with Bel-sar Brachytherapy: Vision Loss/Blindness (~8,000)1
(~2,300)1 (~2,000)2 Indeterminate Lesions and Small PCM Medium/large PCM Early Stage Late Stage Metastatic Disease Chemotherapy (KIMMTRAK) Prevalence: Patients US/EU Clearview & Putnam & Assoc. Market Research Kaliki S, Shields CL. Uveal
melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241-257. doi:10.1038/eye.2016.275
Adverse Event or Adverse Reactions
KIMMTRAK1 Darovasertib + Crizotinib Combination2 Bel-Sar Any Grade Any Grade Any Grade* Cytokine release syndrome 89% Not Disclosed 0% Rash 83% Not Disclosed 0% Pyrexia 76% Not Disclosed 0% Pruritus 69% Not Disclosed 0% Fatigue 64% 40% 0% Nausea 49%
79% 0% Vomiting Not Disclosed 52% 0% Chills 48% Not Disclosed 0% Hypo-/hyperpigmentation 47% Not Disclosed 0% Abdominal pain 45% Not Disclosed 0% Edema 45% 57% 0% dermatitis acneiform Not Disclosed 44% 0% Hypotension Not Disclosed 34% 0%
Hypoalbuminemia Not Disclosed 32% 0% Dizziness Not Disclosed 28% 0% Immunocore Corporate Presentation. 2023 August. Slide 12. https://ir.immunocore.com/static-files/415c5cbb-caae-4ffa-9beb-cb40cfcfc132 IDEAYA Clinical Update Presentation. 2023 April
24. Slide 10. Note: Certain data in this presentation are based on a cross-trial comparisons and are not based on any head-to-head clinical trials. Cross-trial comparisons are inherently limited and may suggest misleading similarities or
differences. Results of head-to-head comparisons may differ significantly from those set forth herein. *Safety outcomes for ongoing Ph2 study with bel-sar presented on slide 22 Bel-sar has Demonstrated a Favorable Profile for the Treatment of
Choroidal Melanoma Ph 2 Data
Ph 2 Trial - Dose Escalation
and Expansion with Suprachoroidal Administration Trial Design - Enrollment Complete (n=22) *Cohort 2: 2 subjects were planned; third subject was additionally enrolled due to dose error in 1 subject **12 patients enrolled, 1 subject who
discontinued after 1 cycle due to unrelated SAEs is not included in data analysis (n=11). Data that follows will be based on a cohort of 11 ClinicalTrials.gov Identifier: NCT04417530 ; AU-011-202 Goal: To Determine Safety, Optimal Dose and
Therapeutic Regimen with Suprachoroidal Administration One Cycle = Doses on days 1, 8, and 15 1 dose- 20 g x 1 Laser 1 dose- 40 g x 1 Laser 1 dose- 40 g x 2 Lasers 2 doses- 40 g x 2 Lasers QWx2 Cohort 1 (n=1) Cohort 2 (n=3*)
Cohort 3 (n=2) Cohort 4 (n=3) Cohort 5 9 doses- 80 g x 2 Lasers QWx3 3 cycles Cohort 6 (n=up to 10) 2 Cycles (n=1)3 Cycles (n=2) N=10 1- 2 Doses (n=9); 2 cycles-6 doses (n=1) N=11** 3 Cycles (9 doses) 6-9 doses- 40 g x 2 Lasers QWx3 Up
to 3 cycles Patient Population Representative of Early-Stage Disease: Indeterminate Lesions and Small Choroidal Melanoma Endpoint Endpoint Definitions Tumor Progression Growth in Tumor Height 0.5mm or 1.5 mm in Largest Basal Diameter
(LBD) Visual Acuity Loss Decrease from Baseline: 15 letters Tumor Thickness Growth Rate Change in Rate of Growth of Tumor Thickness Subtherapeutic Regimens Therapeutic Regimen
High Tumor Control Rates Observed
- Durable at 12 Months Follow Up Dose Response: Subtherapeutic vs Therapeutic Regimen Tumor Progression: change from baseline in thickness 0.5mm; or in LBD 1.5mm confirmed by at least one repeat assessment August 3, 2023, data on
file Aura Biosciences Dose/Regimen Total Patients (n) Total Patients (n) Tumor Control Rate Subtherapeutic Regimens Single dose up to 2 cycles 10 20% (2/10) Therapeutic Regimen 3 Cycles (n=11) 11 73% (8/11) 3 Cycles and Ph 3 eligible (n=10)* 10 80%
(8/10) >90% Completed 12 Months * One subject with circumpapillary tumor that did not meet Ph 3 criteria is not included High Tumor Control Rates with Therapeutic Regimen in Ph 3 Eligible Patients with Active Growth
High Tumor Control Rates Observed
in Ph 3 Population Treated with Therapeutic Regimen August 3, 2023, data on file Aura Biosciences Active Growth and 3 Cycle Regimens (n=10) Progression Definition based on Tumor Thickness (Increase 0.5mm) Change from Baseline in Tumor
Thickness Over 12 Months Treatment Timeframe Follow-up Timeframe Change from Baseline in Tumor Thickness (mm) Subtherapeutic Regimens (n=10) Ph 2 Interim Data Demonstrated Tumor Control Rate of 80%, with 90% of Patients at 12 Months of Follow Up
Change from Baseline in Tumor Thickness (mm) Patients who had documented growth at entry (n=6) Patients who did not have documented growth at entry (n=4) Progression Definition based on Tumor Thickness (Increase 0.5mm) Change from Baseline in
Tumor Thickness Over 12 Months Treatment Timeframe Follow-up Timeframe Patients who had documented growth at entry (n=10)
Ph 2 Interim Data Demonstrated a
Negative Growth Rate Post-Treatment Successful Treatment with 3 Cycle Regimen in Ph 3 Eligible Tumors with Active Growth Change in Tumor Growth (mm/yr) (n=8) August 3, 2023, data on file Aura Biosciences Tumor thickness growth rates/ slopes
estimated using Mixed Models for Repeat Measures (random intercept and slope model for Historical and Study periods) Interim Data Showed Negative Growth Rate Among Responders in Planned Ph 3 Population (P <0.0001) Rate of Tumor Growth (mm/yr) +
0.383 - 0.001 P < 0.0001
. Populations Total Patients (n)